[HTML][HTML] Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
…, MT Sweetser, PP Garg, AK Vaishnaw… - New england journal …, 2018 - Mass Medical Soc
Background Patisiran, an investigational RNA interference therapeutic agent, specifically
inhibits hepatic synthesis of transthyretin. Methods In this phase 3 trial, we randomly assigned …
inhibits hepatic synthesis of transthyretin. Methods In this phase 3 trial, we randomly assigned …
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
…, R Meyers, J Gollob, A Vaishnaw - Proceedings of the …, 2010 - National Acad Sciences
RNA interference (RNAi) is a natural mechanism regulating protein expression that is
mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human …
mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human …
[HTML][HTML] A highly durable RNAi therapeutic inhibitor of PCSK9
…, RS Kauffman, D Kallend, A Vaishnaw… - … England Journal of …, 2017 - Mass Medical Soc
Background Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic
agent that inhibits the synthesis of proprotein convertase subtilisin–kexin type 9 (PCSK9), a …
agent that inhibits the synthesis of proprotein convertase subtilisin–kexin type 9 (PCSK9), a …
[HTML][HTML] Safety and efficacy of RNAi therapy for transthyretin amyloidosis
…, SV Nochur, AK Vaishnaw… - … England Journal of …, 2013 - Mass Medical Soc
Background Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived
transthyretin amyloid in peripheral nerves and the heart. A therapeutic approach mediated by …
transthyretin amyloid in peripheral nerves and the heart. A therapeutic approach mediated by …
A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
…, DJ Wallace, JE Balow, A Vaishnaw… - Arthritis & …, 2003 - Wiley Online Library
Objective CD40–CD40 ligand (CD40L) interactions play a significant role in the production
of autoantibodies and tissue injury in lupus nephritis. We performed an open‐label, multiple‐…
of autoantibodies and tissue injury in lupus nephritis. We performed an open‐label, multiple‐…
A status report on RNAi therapeutics
AK Vaishnaw, J Gollob, C Gamba-Vitalo, R Hutabarat… - Silence, 2010 - Springer
Fire and Mello initiated the current explosion of interest in RNA interference (RNAi) biology
with their seminal work in Caenorhabditis elegans. These observations were closely followed …
with their seminal work in Caenorhabditis elegans. These observations were closely followed …
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
…, SV Nochur, C Gamba-Vitalo, AK Vaishnaw… - Cancer discovery, 2013 - AACR
RNA interference (RNAi) is a potent and specific mechanism for regulating gene expression.
Harnessing RNAi to silence genes involved in disease holds promise for the development …
Harnessing RNAi to silence genes involved in disease holds promise for the development …
Fas Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity
J Drappa, AK Vaishnaw, KE Sullivan… - … England Journal of …, 1996 - Mass Medical Soc
Background The Canale–Smith syndrome is a childhood disorder characterized by
lymphadenopathy and autoimmunity. The similarity between this syndrome and that in mice with the …
lymphadenopathy and autoimmunity. The similarity between this syndrome and that in mice with the …
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy …
…, T Mant, J Chiesa, J Ritter, M Munisamy, AK Vaishnaw… - The Lancet, 2014 - thelancet.com
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors,
leading to their degradation. Genetics studies have shown that loss-of-function mutations in …
leading to their degradation. Genetics studies have shown that loss-of-function mutations in …
[HTML][HTML] Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1
…, MT Sweetser, PP Garg, AK Vaishnaw… - New England journal …, 2021 - Mass Medical Soc
Background Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic
overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and …
overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and …
